Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | HINT1 | P49773 | 4/20 | 0.60 |
| ▸ | NT5E | P21589 | 1/20 | 0.60 |
| ▸ | GSK3A | P49840 | 2/20 | 0.57 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.57 |
| ▸ | TGM2 | P21980 | 1/20 | 0.56 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | PNP | P00491 | 2/20 | 0.54 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17198349 | 1.00 | HPGD (0.64) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL25711664 | 1.00 | HPGD (0.64) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL17198483 | 0.94 | HPGD (0.61) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL1738430 | 0.93 | HPGD (0.60) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL12150668 | 0.93 | HPGD (0.60) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL1738428 | 0.93 | HPGD (0.60) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL12031078 | 0.93 | HPGD (0.60) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL1738429 | 0.93 | HPGD (0.60) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL12746827 | 0.93 | HPGD (0.60) | HPGDHINT1NT5EGSK3ARPS6KA3 | |
| SCHEMBL3417415 | 0.92 | HPGD (0.60) | HPGDHINT1NT5EGSK3ARPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146410-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230144627-A1 | Cyclic Dinucleotides As Sting Agonists | JANSSEN BIOTECH INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20180162899-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | Janssen Biopharma, Inc. | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144627-A1 | Cyclic Dinucleotides As Sting Agonists | STING1, CGAS, MAVS | HPGD 2534/4885HINT1 1207/4885NT5E 554/4885 |
| US-20230146410-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, MAVS | HPGD 2125/4885HINT1 2052/4885NT5E 944/4885 |
| US-20180162899-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, MAVS | HPGD 2534/4885HINT1 1207/4885NT5E 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.